Does SelectHealth Cover Vyvanse? A Complete Insurance Guide

What Is Vyvanse and Why Does Coverage Matter?

Vyvanse is a central nervous system stimulant containing lisdexamfetamine dimesylate. The FDA approved it in 2007 for ADHD and in 2015 for moderate-to-severe binge eating disorder in adults. [1] Because it is a Schedule II controlled substance with significant abuse-deterrent properties compared with immediate-release amphetamines, it occupies a premium price position that makes insurer coverage decisions consequential for patients.

FDA-Approved Indications

The two approved indications affect how SelectHealth adjudicates claims:

• ADHD: Approved for patients age 6 and older. The prescriber's documentation must match the indication; claims submitted under an off-label diagnosis code are routinely rejected.
• Binge eating disorder: Approved for adults only. A 2015 randomized controlled trial (N=267) published in the Journal of Clinical Psychiatry found lisdexamfetamine 50 mg and 70 mg significantly reduced binge eating days per week compared with placebo (P<0.001). [2]

Why Schedule II Status Affects Your Premium

Schedule II drugs require additional pharmacy handling, cannot be refilled without a new written prescription, and face heightened scrutiny during utilization review. Payers including SelectHealth factor this regulatory burden into their prior authorization protocols, requiring more documentation than they would for a non-controlled medication.

Does SelectHealth Cover Vyvanse Specifically?

SelectHealth covers Vyvanse on most of its commercial plan formularies, but places it on a higher tier than generic stimulants. The answer depends on which SelectHealth product you have.

SelectHealth Commercial Plans

Most SelectHealth commercial plans (sold through employers and the individual marketplace in Utah, Idaho, and Nevada) list brand-name Vyvanse on Tier 3 or Tier 4. Tier 3 typically carries a copay of $50, $90 per 30-day fill after deductible; Tier 4 may require coinsurance of 30 to 50% of the negotiated price. Prior authorization is required across all commercial tiers.

Generic lisdexamfetamine, available since the second half of 2023 following Takeda's patent expiration, appears on Tier 2 (preferred generic) on most SelectHealth commercial plans with copays in the $10, $40 range. [3] The FDA confirmed therapeutic equivalence of approved generic versions, meaning the generic carries the same clinical profile. [4]

SelectHealth Medicaid (Select Health Community Care)

SelectHealth administers Select Health Community Care, Utah's largest Medicaid managed care plan. Medicaid formularies are governed by Utah's Medicaid Drug Use Review program and the federal Medicaid Drug Rebate Program. [5] Vyvanse brand appears on the Medicaid formulary as a non-preferred agent requiring prior authorization and documented step therapy. Generic lisdexamfetamine is preferred and typically covered with minimal cost sharing for eligible members.

SelectHealth Medicare Advantage

Medicare Part D plans, including SelectHealth Medicare Advantage, are prohibited by CMS from covering Schedule II stimulants like Vyvanse for ADHD under the standard Part D benefit. [6] Some Medicare Advantage supplemental benefits may cover ADHD-related services, but the drug itself is generally excluded from Part D. Patients in this situation should speak with their prescriber about non-stimulant options such as atomoxetine (Strattera) or viloxazine (Qelbree), both of which are non-scheduled and Part D-eligible.

Prior Authorization Requirements for Vyvanse on SelectHealth

Prior authorization (PA) is the single largest barrier to Vyvanse access on SelectHealth. Understanding the criteria in advance shortens approval timelines significantly.

Typical PA Criteria SelectHealth Uses

SelectHealth's PA criteria for Vyvanse generally align with guidance from the American Academy of Pediatrics (AAP) and the American Academy of Child and Adolescent Psychiatry (AACAP), which recommend stimulant medication as first-line treatment for ADHD. [7] Specific PA requirements typically include:

1. A confirmed diagnosis of ADHD or BED using DSM-5 criteria, documented in the medical record.
2. Prescriber documentation of the patient's age, weight, and relevant comorbidities.
3. Evidence of step therapy: a documented trial of at least one generic methylphenidate or amphetamine product for a minimum of 30 days, with documented inadequate response or intolerance.
4. For BED indication: a psychiatric or primary care diagnosis per DSM-5 criteria and documentation that behavioral therapy was attempted or is being used concurrently.

How Long PA Takes

Most SelectHealth PA requests for Vyvanse are decided within 72 hours for standard requests and 24 hours for urgent requests, consistent with CMS timeliness standards for managed care organizations. [8] Your prescriber's office typically submits the PA; patients can check status through SelectHealth's member portal or by calling the number on the back of the insurance card.

What to Do If SelectHealth Denies Vyvanse

Denials follow a formal appeals process. The first step is an internal appeal, filed within 60 days of the denial notice. If the internal appeal is denied, members have the right to an external independent review. Utah state law requires that external review decisions be binding on the insurer. [9] A 2022 JAMA study found that approximately 54% of prior authorization appeals for brand-name medications were overturned on first internal appeal, underlining the value of submitting a well-documented appeal with clinical notes. [10]

Step Therapy: Which Medications Must You Try First?

Step therapy (also called "fail first") requires patients to try lower-cost alternatives before the plan will cover a higher-cost drug like brand Vyvanse.

First-Line Alternatives SelectHealth Prefers

Generic amphetamine salts (generic Adderall) and generic methylphenidate (generic Ritalin, Concerta) are the most commonly required first steps. These carry Tier 1 or Tier 2 placement on SelectHealth formularies, meaning copays of $5, $20. Both have decades of controlled trial evidence supporting efficacy in ADHD. A 2018 meta-analysis in The Lancet Psychiatry (78 double-blind randomized trials, N=14,000+) rated amphetamines as the most effective pharmacological treatment for adult ADHD on standardized effect-size measures. [11]

Bypassing Step Therapy

Step therapy can be bypassed without a trial of first-line agents when:

• The patient has a documented medical contraindication to the required step agents (e.g., documented cardiovascular adverse events on amphetamine salts).
• The patient has already failed the required step agents at adequate doses and durations, with records provided.
• The patient has a co-occurring condition (e.g., seizure disorder or substance use disorder) that makes the step agent clinically inappropriate per published guidelines.

The AAP's 2019 clinical practice guideline states that medication selection should be individualized based on patient factors including comorbidities, adherence barriers, and prior medication history. [7]

What Does Vyvanse Cost With SelectHealth Coverage?

Cost depends on whether you have met your deductible, your plan tier placement, and whether you use brand or generic.

Cost Breakdown by Scenario

| Scenario | Estimated Monthly Cost | |---|---| | Brand Vyvanse, Tier 3, deductible met | $50, $90 copay | | Brand Vyvanse, Tier 4, deductible met | $100, $200 coinsurance | | Brand Vyvanse, deductible NOT met | $380, $450 (full negotiated price) | | Generic lisdexamfetamine, Tier 2, deductible met | $10, $40 copay | | Generic lisdexamfetamine, deductible NOT met | $90, $150 (full negotiated price) |

These figures reflect 2024 to 2025 typical SelectHealth commercial plan structures and will vary by specific plan.

Takeda's Vyvanse Savings Card

Takeda Pharmaceuticals offers a Vyvanse Savings Card for commercially insured patients. Eligible patients may pay as little as $30 per 30-day supply for up to 24 months. The card is NOT valid for patients covered by Medicaid, Medicare, or any other federal or state government-funded health program. [12] Check eligibility at the Vyvanse manufacturer website or ask your pharmacy.

GoodRx and Discount Programs

GoodRx and similar discount programs can reduce brand Vyvanse cost at cash-pay pharmacies to approximately $280, $330 per month, still well above the generic alternative. Generic lisdexamfetamine via GoodRx can be obtained for $45, $90 at many pharmacies, making it the most cost-effective option for patients whose plan does not cover brand Vyvanse.

Generic Lisdexamfetamine: The Practical Alternative

Generic lisdexamfetamine dimesylate received FDA approval for multiple manufacturers starting in 2023. The FDA's Orange Book lists these generics as AB-rated, meaning they are considered therapeutically equivalent to brand Vyvanse. [4]

Clinical Equivalence

The FDA requires AB-rated generics to demonstrate bioequivalence within a 80 to 125% confidence interval for key pharmacokinetic parameters. [13] For most patients with ADHD or BED, switching from brand Vyvanse to an AB-rated generic produces no clinically meaningful difference in effect. The American Academy of Pediatrics has stated that generic substitution for ADHD medications is acceptable when bioequivalence is established. [7]

Formulary Position of the Generic

On most SelectHealth commercial plans, generic lisdexamfetamine is covered at Tier 2 without prior authorization, or with a streamlined PA that requires only diagnosis confirmation. This is a significant administrative simplification compared with brand Vyvanse's Tier 3 or 4 PA pathway.

Non-Stimulant Alternatives Covered by SelectHealth

Patients who cannot tolerate stimulants, fail step therapy in the other direction, or are on Medicare Part D have several non-stimulant options covered under SelectHealth plans.

Atomoxetine (Strattera)

Atomoxetine is a selective norepinephrine reuptake inhibitor approved for ADHD in children age 6+, adolescents, and adults. Generic atomoxetine has been available since 2017 and sits on Tier 1 or 2 for most SelectHealth plans. A Cochrane systematic review (36 trials, N=5,765) found atomoxetine significantly reduced ADHD symptoms versus placebo in children and adults. [14]

Viloxazine (Qelbree)

Viloxazine extended-release is a non-stimulant approved by the FDA in 2021 for ADHD in patients ages 6 and older. [15] It is a serotonin norepinephrine modulating agent and is not a controlled substance, making it Part D-eligible for Medicare patients. SelectHealth commercial plans vary on its tier placement; check your specific formulary.

Clonidine and Guanfacine Extended-Release

Clonidine ER (Kapvay) and guanfacine ER (Intuniv) are alpha-2 agonists with FDA ADHD approvals. Generics are widely available and typically sit on Tier 1 for SelectHealth plans. They are often used as adjuncts rather than monotherapy but represent a viable primary option for patients with significant cardiovascular or anxiety contraindications to stimulants.

How to Get Vyvanse Covered by SelectHealth: Step-by-Step

Getting coverage approved efficiently requires preparation.

Step 1: Confirm Your Formulary

Log in to the SelectHealth member portal at selecthealth.org and search for lisdexamfetamine or Vyvanse in the drug lookup tool. Confirm the tier, PA requirements, and any quantity limits before your appointment.

Step 2: Ask Your Prescriber to Submit a PA With Full Documentation

A PA submitted with complete documentation on the first attempt has a higher approval rate. Your prescriber should include DSM-5 diagnosis documentation, prior medication history with specific doses tried and duration, reason for requesting brand over generic (if applicable), and relevant comorbidities. The AACAP recommends that prescribers document functional impairment alongside symptom scales such as the Conners Rating Scale or ADHD-RS-5 to strengthen medical necessity arguments. [16]

Step 3: Request Peer-to-Peer Review if Denied

If the initial PA is denied, your prescriber can request a peer-to-peer review, where they speak directly with SelectHealth's reviewing physician. These conversations frequently resolve borderline cases.

Step 4: File a Formal Appeal With Supporting Literature

If peer-to-peer fails, file a formal internal appeal. Attach the AAP or AACAP clinical guideline language supporting your specific situation. As noted above, approximately 54% of first-level appeals for brand medications are overturned. [10]

Step 5: Request External Review

If the internal appeal is denied, request an independent external review. Utah law requires external reviewers to apply evidence-based clinical standards, not just formulary policy.

Quantity Limits and Prescription Rules for Vyvanse

SelectHealth, like most payers, applies quantity limits (QL) to Schedule II stimulants. Vyvanse is typically limited to a 30-day supply per fill, consistent with federal DEA regulations that prohibit refills on Schedule II prescriptions. [17] SelectHealth does not allow early refills on Vyvanse; the prescription must be filled within a defined dispensing window (usually no more than 5 days early). Vacation overrides may be available through SelectHealth's pharmacy benefit manager for documented travel needs.

Special Populations

Children and Adolescents

SelectHealth covers Vyvanse for pediatric ADHD patients age 6 and older, matching the FDA label. [1] PA criteria for pediatric patients typically require confirmation that a pediatrician or child psychiatrist established the diagnosis.

Adults With Binge Eating Disorder

For the BED indication, SelectHealth PA criteria typically require that the prescriber document that BED meets DSM-5 severity thresholds (average of at least one binge eating episode per week for 3 months), that the patient has attempted or is engaged in cognitive behavioral therapy, and that weight loss is NOT the primary goal of treatment (as Vyvanse is not FDA-approved for obesity). [1]

Pregnant Patients

Amphetamines, including lisdexamfetamine, are associated with adverse neonatal outcomes when used during pregnancy. The FDA label carries specific warnings about neonatal withdrawal and premature delivery. [1] SelectHealth PA criteria for pregnant patients with ADHD typically require specialist documentation and a risk-benefit discussion. Non-stimulant alternatives are generally preferred during pregnancy per ACOG guidance. [18]